Table 2.
List of the mean values of the considered cardiovascular parameters in the subsequent phases of the pilot study.
| Parameter | Phase | ||||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
| HR (bpm) | 72.65 | 84.90** | 67.69† | 84.81§ | 67.65§ | 100.49** | 64.12‡ |
| SD | ±12.01 | ±16.52 | ±8.05 | ±11.99 | ±11.02 | ±14.75 | ±10.00 |
| Rel HR (%) | 0 | 16.87** | −5.98† | 17.68§ | −6.70§ | 39.49** | −11.19‡ |
| SD | 0 | ±11.04 | ±7.18 | ±10.78 | ±4.51 | ±14.65 | ±8.65 |
| IBI (ms) | 856.07 | 742.87** | 906.83† | 725.21§ | 917.71§ | 614.53** | 967.23‡ |
| SD | ±149.01 | ±138.30 | ±117.25 | ±97.43 | ±151.74 | ±88.87 | ±156.26 |
| Rel IBI (%) | 0 | −13.15** | 6.81† | −14.53§ | 7.42§ | −27.58** | 13.66‡ |
| SD | 0 | ±7.80 | ±7.59 | ±8.26 | ±5.43 | ±7.70 | ±11.44 |
| SBP (mmHg) | 123.39 | 117.62 | 126.08 | 130.47† | 126.42 | 132.54* | 131.63* |
| SD | ±16.01 | ±14.52 | ±18.83 | ±20.68 | ±17.41 | ±25.57 | ±25.47 |
| Rel SBP (%) | 0 | −4.30 | 2.85 | 5.96† | 2.76 | 7.31* | 6.37* |
| SD | 0 | ±7.79 | ±14.69 | ±11.18 | ±10.42 | ±12.01 | ±10.58 |
| DBP (mmHg) | 76.31 | 73.31 | 71.40 | 90.02† | 72.54 | 94.06‡ | 71.83 |
| SD | ±17.32 | ±11.11 | ±10.95 | ±11.71 | ±17.94 | ±11.83 | ±12.18 |
| Rel DBP (%) | 0 | −1.11 | −1.66 | 22.56† | −1.986 | 28.78‡ | −1.99 |
| SD | 0 | ±17.76 | ±30.22 | ±28.18 | ±28.76 | ±33.02 | ±27.11 |
| MAP (mmHg) | 93.02 | 87.00 | 90.68 | 103.47‡ | 91.68 | 105.12* | 91.93 |
| SD | ±17.14 | ±13.48 | ±13.41 | ±14.60 | ±15.44 | ±13.97 | ±15.17 |
| Rel MAP (%) | 0 | −5.39 | −0.70 | 12.73‡ | −0.35 | 15.04* | 0.21 |
| SD | 0 | ±11.64 | ±17.47 | ±14.19 | ±15.29 | ±18.52 | ±16.27 |
| SV (ml) | 88.98 | 69.36* | 102.04 | 54.79† | 105.38 | 42.65§ | 107.49* |
| SD | ±32.77 | ±26.04 | ±24.60 | ±22.90 | ±65.52 | ±15.61 | ±38.31 |
| Rel SV (%) | 0 | −19.75* | 26.37 | −34.09† | 20.23 | −47.50§ | 28.51* |
| SD | 0 | ±26.43 | ±45.90 | ±30.00 | ±56.43 | ±25.05 | ±46.22 |
| CO (l/min) | 6.50 | 5.85* | 7.03 | 4.58* | 6.90 | 4.31† | 7.03 |
| SD | ±2.34 | ±1.93 | ±2.42 | ±1.70 | ±3.95 | ±1.55 | ±2.66 |
| Rel CO (%) | 0 | −7.16* | 15.36 | −25.49* | 8.44 | −29.52† | 12.15 |
| SD | 0 | ±26.36 | ±40.13 | ±30.00 | ±52.04 | ±28.27 | ±36.89 |
| LVET (ms) | 325.25 | 255.28** | 328.76 | 256.89** | 331.55 | 241.8§ | 333.84 |
| SD | ±15.84 | ±26.47 | ±14.21 | ±22.77 | ±17.66 | ±34.65 | ±17.97 |
| Rel LVET (%) | 0 | −21.45** | 1.18 | −20.87** | 2.01 | −25.35§ | 2.79 |
| SD | 0 | ±7.85 | ±3.96 | ±7.70 | ±4.51 | ±12.79 | ±5.99 |
| RPP (mmHg/min) | 0.92 × 104 | 1.03 × 104† | 0.86 × 104 | 1.11 × 104§ | 0.86 × 104† | 1.36 × 104** | 0.87 × 104 |
| SD | ±0.23 × 104 | ±0.22 × 104 | ±0.19 × 104 | ±0.20 × 104 | ±0.21 × 104 | ±0.31 × 104 | ±0.22 × 104 |
| Rel RPP (%) | 0 | 12.28 × 104† | −5.23 × 104 | 23.07 × 104§ | −6.70 × 104† | 51.05 × 104** | −3.43 × 104 |
| SD | 0 | ±12.44 × 104 | ±14.66 × 104 | ±19.73 × 104 | ±10.59 × 104 | ±36.55 × 104 | ±24.02 × 104 |
| TPR (MU) | 1.20 | 1.03 | 0.91 | 1.62* | 1.11 | 1.68 | 0.90* |
| SD | ±0.61 | ±0.48 | ±0.33 | ±0.73 | ±0.46 | ±0.61 | ±0.35 |
| Rel TPR (%) | 0 | −0.31 | 2.25 | 67.55* | 6.14 | 74.28 | −8.46* |
| SD | 0 | ±49.98 | ±84.36 | ±103.12 | ±53.95 | ±101.34 | ±56.28 |
The significance levels for changes in the mean values obtained in the subsequent phases are shown in relation to those obtained in phase 1.
Rel - relative values calculated with reference to the initial level in phase 1.
MU - medical units.
Levels of significance.
*p ≤ 0.05; †p ≤ 0.01; ‡p ≤ 0.005; §p ≤ 0.0005; **p ≤ 0.00005.